Patients' Preferences and Expectations in Overactive Bladder: A Systematic Review

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Jan 21

PMID 36675324

Authors

Antonio Cicione

Riccardo Lombardo

Vincenzo Umbaca

Giorgia Tema

Giacomo Gallo

Jordi Stira

Carmen Gravina

Beatrice Turchi

Antonio Franco

Elisa Mancini

Antonio Nacchia

Rocco Damiano

Andrea Tubaro

Cosimo De Nunzio

Affiliations

Soon will be listed here.

Abstract

The aim of our study is to review the current available knowledge regarding preferences and expectations of patients with overactive bladder (OAB). The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement guidelines were followed for this manuscript's preparation. Three online databases were searched: PubMed/Medline, Embase, and Scopus, while a combination of the following keywords was used: detrusor overactivity, overactive bladder, urinary incontinence, perspectives, expectations, and preferences. Overall, 1349 studies were retrieved and screened while only 10 studies appeared to be relevant for the scope of this review. Most of the studies were related to preferences about OAB medications (i.e., antimuscarinics); four of them reported patients' inclinations to alternative treatments in the case of medication therapy failure (i.e., neuromodulation, Botox). No data were found about diagnosis or other aspects of disease management (i.e., surgery, follow-up). Based on these findings, from the patient's point of view, the ideal medication should be cheap, without risk of cognitive function impairment, and able to reduce daytime urinary frequency and incontinence episodes.

Citing Articles

Special Issue: "Latest Advances on Urinary Incontinence".

Bientinesi R, Gavi F, Li Marzi V, Sacco E J Clin Med. 2023; 12(22).

PMID: 38002688 PMC: 10672451. DOI: 10.3390/jcm12227075.

References

Sahakyan Y, Erman A, Bhojani N, Chughtai B, Zorn K, Sander B . Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study. Prostate Cancer Prostatic Dis. 2022; 26(1):113-118. DOI: 10.1038/s41391-022-00561-2. View

Swinburn P, Lloyd A, Ali S, Hashmi N, Newal D, Najib H . Preferences for antimuscarinic therapy for overactive bladder. BJU Int. 2010; 108(6):868-73. DOI: 10.1111/j.1464-410X.2010.09882.x. View

Ryan M, Scott D, Donaldson C . Valuing health care using willingness to pay: a comparison of the payment card and dichotomous choice methods. J Health Econ. 2004; 23(2):237-58. DOI: 10.1016/j.jhealeco.2003.09.003. View

Kini V, Ho P . Interventions to Improve Medication Adherence: A Review. JAMA. 2018; 320(23):2461-2473. DOI: 10.1001/jama.2018.19271. View

Chhatre S, Newman D, Wein A, Jayadevappa R . Patient preference elicitation instrument, OABCare, to facilitate shared decision-making in the care of overactive bladder. Neurourol Urodyn. 2021; 40(3):791-801. DOI: 10.1002/nau.24618. View

Sexton C, Notte S, Maroulis C, Dmochowski R, Cardozo L, Subramanian D . Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011; 65(5):567-85. DOI: 10.1111/j.1742-1241.2010.02626.x. View

Huang J, Chan C, Yee S, Deng Y, Bai Y, Chan S . Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2022; 26(2):421-428. DOI: 10.1038/s41391-022-00610-w. View

De Nunzio C, Presicce F, Pirozzi L, Castellan P, Schips L, Cindolo L . The Current Indications and the Benefits of Combining a β3-Agonist with an Anticholinergic for the Treatment of OAB. Curr Drug Targets. 2015; 16(11):1198-206. DOI: 10.2174/1389450116666150806124345. View

De Nunzio C, Cicione A, Izquierdo L, Lombardo R, Tema G, Lotrecchiano G . Multicenter Analysis of Postoperative Complications in Octogenarians After Radical Cystectomy and Ureterocutaneostomy: The Role of the Frailty Index. Clin Genitourin Cancer. 2019; 17(5):402-407. DOI: 10.1016/j.clgc.2019.07.002. View

10.

Ryan M, Gerard K . Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy. 2003; 2(1):55-64. View

11.

Heisen M, Baeten S, Verheggen B, Stoelzel M, Hakimi Z, Ridder A . Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments. Curr Med Res Opin. 2016; 32(4):787-96. DOI: 10.1185/03007995.2016.1142959. View

12.

Ornaghi P, Porreca A, Sandri M, Sciarra A, Falsaperla M, Ludovico G . Features of patients referring to the outpatient office due to benign prostatic hyperplasia: analysis of a national prospective cohort of 5815 cases. Prostate Cancer Prostatic Dis. 2022; 26(4):730-735. DOI: 10.1038/s41391-022-00575-w. View

13.

Benner J, Nichol M, Rovner E, Jumadilova Z, Alvir J, Hussein M . Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2009; 105(9):1276-82. DOI: 10.1111/j.1464-410X.2009.09036.x. View

14.

Vouri S, Kebodeaux C, Stranges P, Teshome B . Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis. Arch Gerontol Geriatr. 2016; 69:77-96. PMC: 5516911. DOI: 10.1016/j.archger.2016.11.006. View

15.

Wu J, Fulton R, Amundsen C, Knight S, Kuppermann M . Patient preferences for different severities of and treatments for overactive bladder. Female Pelvic Med Reconstr Surg. 2012; 17(4):184-9. DOI: 10.1097/SPV.0b013e318223c8ad. View

16.

Watson V, Ryan M, Brown C, Barnett G, Ellis B, Emberton M . Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2004; 172(6 Pt 1):2321-5. DOI: 10.1097/01.ju.0000140957.31325.7f. View

17.

Harpe S, Szeinbach S, Caswell R, Corey R, McAuley J . The relative importance of health related quality of life and prescription insurance coverage in the decision to pharmacologically manage symptoms of overactive bladder. J Urol. 2007; 178(6):2532-6. DOI: 10.1016/j.juro.2007.08.006. View

18.

Bai F, Ling J, Esoimeme G, Yao L, Wang M, Huang J . A systematic review of questionnaires about patient's values and preferences in clinical practice guidelines. Patient Prefer Adherence. 2018; 12:2309-2323. PMC: 6220727. DOI: 10.2147/PPA.S177540. View

19.

Decalf V, Huion A, Benoit D, Denys M, Petrovic M, Everaert K . Older People's Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment. Drugs Aging. 2017; 34(8):615-623. DOI: 10.1007/s40266-017-0474-6. View

20.

Athavale A, Gooch K, Walker D, Suh M, Scaife J, Haber A . A patient-reported, non-interventional, cross-sectional discrete choice experiment to determine treatment attribute preferences in treatment-naïve overactive bladder patients in the US. Patient Prefer Adherence. 2018; 12:2139-2152. PMC: 6190636. DOI: 10.2147/PPA.S178668. View